GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » ROE %

Regenerex Pharma (Regenerex Pharma) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Regenerex Pharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Regenerex Pharma's annualized net income for the quarter that ended in Dec. 2023 was $-1.06 Mil. Regenerex Pharma's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-3.75 Mil. Therefore, Regenerex Pharma's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Regenerex Pharma's ROE % or its related term are showing as below:

PEPT's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.54
* Ranked among companies with meaningful ROE % only.

Regenerex Pharma ROE % Historical Data

The historical data trend for Regenerex Pharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma ROE % Chart

Regenerex Pharma Annual Data
Trend Nov09 Nov10 Nov11 Nov12 Nov13 Nov14 Mar17 Mar18 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Equity - - - -

Regenerex Pharma Quarterly Data
May14 Aug14 Nov14 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenerex Pharma's ROE %

For the Medical Instruments & Supplies subindustry, Regenerex Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerex Pharma's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regenerex Pharma's ROE % distribution charts can be found below:

* The bar in red indicates where Regenerex Pharma's ROE % falls into.



Regenerex Pharma ROE % Calculation

Regenerex Pharma's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-0.137/( (-0.986+-1.123)/ 2 )
=-0.137/-1.0545
=N/A %

Regenerex Pharma's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-1.056/( (-3.633+-3.876)/ 2 )
=-1.056/-3.7545
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Regenerex Pharma  (OTCPK:PEPT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1.056/-3.7545
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.056 / 0)*(0 / 0.8925)*(0.8925 / -3.7545)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1.056/-3.7545
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1.056 / -1.056) * (-1.056 / -0.956) * (-0.956 / 0) * (0 / 0.8925) * (0.8925 / -3.7545)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1046 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Regenerex Pharma ROE % Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerex Pharma (Regenerex Pharma) Business Description

Traded in Other Exchanges
N/A
Address
5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines